
Hims & Hers (HIMS) shares rallied another 6% in premarket today after Eli Lilly (LLY) warned of health risks from impurity it discovered in the compounded version of its weight-loss drug.
This helped HIMS push higher as the company just announced a truce and partnership with Ozempic- and Wegovy-maker Novo Nordisk (NVO), reinforcing its transition from a high-risk “gray market” pharmacy to a legitimate, sanctioned distribution partner for Big Pharma.